Chk1 inhibition in p53 deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death

Cell Cycle

Volumn 13, Issue 2, 2014, Pages 303-314

  Del Nagro, Christopher J ^a   Choi, Jonathan ^a   Xiao, Yang ^a   Rangell, Linda ^a   Mohan, Sankar ^a,b   Pandita, Ajay ^a,b   Zha, Jiping ^a,c   Jackson, Peter K ^a,d   O'Brien, Thomas ^a  

^a GENENTECH INC   (United States)

^b OncoMDx Laboratories   (United States)

^c Crown Bioscience   (China)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Checkpoint bypass; Chemo potentiation; Chk1; Gemcitabine; GNE 783; P53

Indexed keywords

CASPASE; CHECKPOINT KINASE 1; DNA; GEMCITABINE; GNE 783; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; CARBOLINE DERIVATIVE; CELL CYCLE PROTEIN; DEOXYCYTIDINE; GNE-783; NUCLEAR PROTEIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RAD51 PROTEIN; WEE1 PROTEIN, HUMAN;

ARTICLE; CELL DEATH; CELL STRAIN HT29; CHROMOSOME; CONTROLLED STUDY; DNA CONTENT; DNA DAMAGE; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL; HUMAN; HUMAN CELL; METAPHASE; MITOSIS; PHASE TRANSITION; S PHASE CELL CYCLE CHECKPOINT; ANALOGS AND DERIVATIVES; DNA FRAGMENTATION; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; HUMAN CHROMOSOME; METABOLISM; TUMOR CELL LINE;

CARBOLINES; CASPASES; CELL CYCLE PROTEINS; CELL DEATH; CELL LINE, TUMOR; CHROMOSOMES, HUMAN; DEOXYCYTIDINE; DNA FRAGMENTATION; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MITOSIS; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; RAD51 RECOMBINASE; S PHASE CELL CYCLE CHECKPOINTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84892600934     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27055     Document Type: Article

References (56)

1. Schlegel R, Pardee AB. Caffeine-induced uncoupling of mitosis from the completion of DNA replication in mammalian cells. Science 1986; 232:1264-6; PMID:2422760; http://dx.doi.org/10.1126/science.2422760 (Pubitemid 16066004)
2. Nghiem P, Park PK, Kim Y, Vaziri C, Schreiber SL. ATR inhibition selectively sensitizes G1 checkpointdeficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci U S A 2001; 98: 9092-7; PMID:11481475; http://dx.doi.org/10.1073/pnas.161281798 (Pubitemid 32743874)
3. Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 2005; 65: 6835-42; PMID:16061666; http://dx.doi.org/10. 1158/0008-5472.CAN-04-2246 (Pubitemid 41060722)
4. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. 2006:v7-12
5. Dyke JH, Ellwood C, Gancia E, Gazzard LJ, Goodacre S, Kintz S, Lyssikatos J, Macleod C, Williams K. Diazacarbazoles and methods of use. World Intellectual Property Organization: Genentech Inc. 2009
6. Xiao Y, Ramiscal J, Kowanetz K, Del Nagro C, Malek S, Evangelista M, Blackwood E, Jackson PK, O'Brien T. Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor. Mol Cancer Ther 2013; 12: 2285-95; PMID:24038068; http://dx.doi.org/10.1158/1535-7163.MCT-13-0404
7. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008; 7: 2394-404; PMID:18723486; http://dx.doi.org/10.1158/1535-7163.MCT- 07-2391
8. Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, Taricani L, Wiswell D, Seghezzi W, Penaflor E, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther 2011; 10: 591-602; PMID:21321066; http://dx.doi.org/10.1158/1535-7163.MCT-10-0928
9. Montano R, Chung I, Garner KM, Parry D, Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNAdamaging agents and antimetabolites. Mol Cancer Ther 2012; 11: 427-38; PMID:22203733; http://dx.doi.org/10.1158/1535-7163.MCT-11-0406
10. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70: 4972-81; PMID:20501833; http://dx.doi.org/10.1158/0008-5472.CAN-09- 3573
11. Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, Ma S, Moler EJ, Ni ZJ, Lopes de Menezes DE, et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 2007; 13: 591-602; PMID:17255282; http://dx.doi.org/10. 1158/1078-0432.CCR-06-1424 (Pubitemid 46225366)
12. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7: 2955-66; PMID:18790776; http://dx.doi.org/10.1158/1535- 7163.MCT-08-0492
13. Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 2007; 6: 1239-48; PMID:17406032; http://dx.doi.org/10.1158/1535-7163.MCT-06-0633 (Pubitemid 46711987)
14. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011; 17: 88-96; PMID:21087899; http://dx.doi.org/10.1016/j.molmed.2010.10.009
15. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770-83; PMID:16603719; http://dx.doi.org/10. 1200/JCO.2005.03.7689 (Pubitemid 46628473)
16. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262-7; PMID:14981513; http://dx.doi.org/10.1038/nm1003 (Pubitemid 38667616)
17. Hirota T, Lipp JJ, Toh BH, Peters JM. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 2005; 438: 1176-80; PMID:16222244; http://dx.doi.org/10.1038/nature04254 (Pubitemid 41831689)
18. van Vugt MA, Brás A, Medema RH. Polo-like kinase-1 controls recovery from a G2 DNA damage- induced arrest in mammalian cells. Mol Cell 2004; 15: 799-811; PMID:15350223; http://dx.doi.org/10.1016/j.molcel.2004.07.015 (Pubitemid 39194909)
19. Bassermann F, Frescas D, Guardavaccaro D, Busino L, Peschiaroli A, Pagano M. The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 2008; 134: 256-67; PMID:18662541; http://dx.doi.org/10.1016/j.cell.2008.05. 043 (Pubitemid 352010329)
20. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17: 316-22; PMID:17291758; http://dx.doi.org/10.1016/j. cub.2006.12.037 (Pubitemid 46241881)
21. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008; 14: 111-22; PMID:18656424; http://dx.doi.org/10.1016/j.ccr.2008.07. 002
22. Zachos G, Black EJ, Walker M, Scott MT, Vagnarelli P, Earnshaw WC, Gillespie DAF. Chk1 is required for spindle checkpoint function. Dev Cell 2007; 12:247-60; PMID:17276342; http://dx.doi.org/10.1016/j.devcel.2007.01.003 (Pubitemid 46193970)
23. Peddibhotla S, Lam MH, Gonzalez-Rimbau M, Rosen JM. The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis. Proc Natl Acad Sci U S A 2009; 106: 5159-64; PMID:19289837; http://dx.doi.org/10.1073/pnas.0806671106
24. Tang J, Erikson RL, Liu X. Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1). Proc Natl Acad Sci U S A 2006; 103: 11964-9; PMID:16873548; http://dx.doi.org/ 10.1073/pnas.0604987103 (Pubitemid 44215794)
25. Bayani J, Squire JA. Advances in the detection of chromosomal aberrations using spectral karyotyping. Clin Genet 2001; 59: 65-73; PMID:11260203; http://dx.doi.org/10.1034/j.1399-0004.2001.590201.x (Pubitemid 32220017)
26. Karpenshif Y, Bernstein KA. From yeast to mammals: recent advances in genetic control of homologous recombination. DNA Repair (Amst) 2012; 11:781-8; PMID:22889934; http://dx.doi.org/10.1016/j.dnarep.2012.07.001
27. Blackwood E, Epler J, Yen I, Flagella M, O'Brien T, Evangelista M, Schmidt S, Xiao Y, Choi J, Kowanetz K, et al. Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. Mol Cancer Ther 2013; 12: 1968-80; PMID:23873850; http://dx.doi.org/10.1158/1535-7163.MCT-12- 1218
28. Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Kovar P, Li G, Wang G, Tao Z-F, Tong Y, et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer 2006; 119: 2784-94; PMID:17019715; http://dx.doi.org/10.1002/ijc.22198 (Pubitemid 44846229)
29. Ganzinelli M, Carrassa L, Crippa F, Tavecchio M, Broggini M, Damia G. Checkpoint Kinase 1 Down- Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil 2008: 5131-41
30. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-501; PMID:9822382; http://dx.doi.org/10. 1126/science.282.5393.1497 (Pubitemid 28538613)
31. Garner E, Raj K. Protective mechanisms of p53- p21-pRb proteins against DNA damage-induced cell death. Cell Cycle 2008; 7: 277-82; PMID:18235223; http://dx.doi.org/10.4161/cc.7.3.5328 (Pubitemid 351366487)
32. Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992; 257:1955-7; PMID:1384126; http://dx.doi.org/10.1126/science.1384126
33. De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJF, Würdinger T. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 2011; 17:4200-7; PMID:21562035; http://dx.doi.org/10.1158/1078-0432.CCR-10-2537
34. Maya-Mendoza A, Petermann E, Gillespie DAF, Caldecott KW, Jackson DA. Chk1 regulates the density of active replication origins during the vertebrate S phase. EMBO J 2007; 26: 2719-31; PMID:17491592; http://dx.doi.org/10.1038/sj. emboj.7601714 (Pubitemid 46884282)
35. Petermann E, Woodcock M, Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci U S A 2010; 107: 16090-5; PMID:20805465; http://dx.doi.org/10.1073/pnas.1005031107
36. Scorah J, McGowan CH. Claspin and Chk1 regulate replication fork stability by different mechanisms. Cell Cycle 2009; 8: 1036-43; PMID:19270516; http://dx.doi.org/10.4161/cc.8.7.8040
37. Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, Boxall KJ, Aherne GW, Eccles SA, Raynaud FI, et al. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther 2010; 9: 89-100; PMID:20053762; http://dx.doi.org/10.1158/1535-7163.MCT-09-0938
38. Young JD, Yao SYM, Sun L, Cass CE, Baldwin SA. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 2008; 38: 995-1021; PMID:18668437; http://dx.doi.org/10. 1080/00498250801927427
39. Carrassa L, Damia G. Unleashing Chk1 in cancer therapy. Cell Cycle 2011; 10: 2121-8; PMID:21610326; http://dx.doi.org/10.4161/cc.10.13.16398
40. Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, Tai A, Wagner JM, Miller N, Kim YD, et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 2007; 6:104-10; PMID:17245119; http://dx.doi.org/10.4161/cc.6.1.3699 (Pubitemid 46173886)
41. McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S, Pommier Y, Schwartz G, Tse A. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNAdependent protein kinase. Cell Cycle 2010; 9:995-1004; PMID:20160494; http://dx.doi.org/10.4161/cc.9.5.10935
42. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, Helleday T, Sehested M, Lukas J, Bartek J. Inhibition of Human Chk1 Causes Increased Initiation of DNA Replication, Phosphorylation of ATR Targets, and DNA Breakage. 2005: 3553-62
43. Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence TS, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009; 8: 45-54; PMID:19139112; http://dx.doi.org/10.1158/1535-7163.MCT-08-0662
44. Costanzo V. Brca2, Rad51 and Mre11: performing balancing acts on replication forks. DNA Repair (Amst) 2011; 10: 1060-5; PMID:21900052; http://dx.doi.org/10.1016/j.dnarep.2011.07.009
45. On KF, Chen Y, Ma HT, Chow JPH, Poon RYC. Determinants of mitotic catastrophe on abrogation of the G2 DNA damage checkpoint by UCN-01. Mol Cancer Ther 2011; 10: 784-94; PMID:21430130; http://dx.doi.org/10.1158/1535-7163.MCT- 10-0809
46. Riesterer O, Matsumoto F, Wang L, Pickett J, Molkentine D, Giri U, Milas L, Raju U. A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe. Invest New Drugs 2011; 29: 514-22; PMID:20024691; http://dx.doi.org/10.1007/s10637-009-9361-2
47. Andersen JL, Johnson CE, Freel CD, Parrish AB, Day JL, Buchakjian MR, Nutt LK, Thompson JW, Moseley MA, Kornbluth S. Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2. EMBO J 2009; 28: 3216-27; PMID:19730412; http://dx.doi.org/10.1038/emboj.2009.253
48. Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff SD, Cook JA. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010; 16: 2076-84; PMID:20233881; http://dx.doi.org/10.1158/1078-0432.CCR-09-3277
49. Origanti S, Cai SR, Munir AZ, White LS, Piwnica- Worms H. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 2013; 32: 577-88; PMID:22430210; http://dx.doi.org/10.1038/onc.2012.84
50. Innocente SA, Lee JM. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription. FEBS Lett 2005; 579: 1001-7; PMID:15710382; http://dx.doi.org/10.1016/j.febslet.2004.12.073 (Pubitemid 40248660)
51. Xiao Z, Xue J, Gu W-Z, Bui M, Li G, Tao Z-F, Lin N-H, Sowin TJ, Zhang H. Cyclin B1 is an efficacypredicting biomarker for Chk1 inhibitors. Biomarkers 2008; 13: 579-96; PMID:18671143; http://dx.doi.org/10.1080/13547500802063240
52. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8: 2992-3000; PMID:19887545; http://dx.doi.org/10. 1158/1535-7163.MCT-09-0463
53. Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G, Biasco G. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). [Review]. Oncol Rep 2010; 23: 1183-92; PMID:20372829; http://dx.doi.org/10.3892/or-00000749
54. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A 2003; 100: 7977-82; PMID:12799470; http://dx.doi.org/10.1073/pnas.1337088100 (Pubitemid 36760080)
55. Pandita A, Bayani J, Paderova J, Marrano P, Graham C, Barrett M, Prasad M, Zielenska M, Squire JA. Integrated cytogenetic and high-resolution array CGH analysis of genomic alterations associated with MYCN amplification. Cytogenet Genome Res 2011; 134: 27-39; PMID:21508638; http://dx.doi.org/10.1159/000324698
56. Schröck E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, et al. Multicolor spectral karyotyping of human chromosomes. Science 1996; 273: 494-7; PMID:8662537; http://dx.doi.org/10.1126/science.273.5274.494 (Pubitemid 26286449)